This presentation contains forward-looking statements (made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995). By their nature, forward-looking statements involve risk and uncertainty. Forward-looking statements represent the company's judgment regarding future events, and are based on currently available information. Consequently the company cannot guarantee their accuracy and their completeness and actual results may differ materially from those the company anticipated due to a number of uncertainties, many of which the company is not aware of. For additional information concerning these and other important factors that may cause the company's actual results to differ materially from expectations and underlying assumptions, please refer to the reports filed by the company with the ‘Autorité des Marchés Financiers’.
Cegedim

80 Countries
Presence

€902m
2013 Revenue

€156m
2013 EBITDA

B+
Stable Outlook
S&P Rating

Makes healthcare business run more efficiently
Cegedim has received from IMS Health a binding offer for the major part of the CRM and Strategic Data division\(^{(1)}\) for €385 million.

The option is valid until November 30, 2014.

---

1. CRM & STRATEGIC DATA
   - FOR LIFE SCIENCES COMPANIES
   - 2013 % Group Revenue: 50%, €463m
   - 2013 % Group EBIT\(^{(2)}\): 42%, €38m

2. HEALTHCARE PROFESSIONALS
   - FOR HEALTHCARE PROFESSIONALS
   - 2013 % Group Revenue: 32%, €289m
   - 2013 % Group EBIT\(^{(2)}\): 39%, €38m

3. INSURANCE & SERVICES
   - FOR HEALTHCARE INSURANCE
   - 2013 % Group Revenue: 18%, €160m
   - 2013 % Group EBIT\(^{(2)}\): 27%, €25m

---

\(^{(1)}\) Excluding the French company GERS, the Cegedim Romania department that performs GERS Sales Audit activities and Pharmastock.

\(^{(2)}\) Before special items.
From an industrial perspective the proposed transaction is a response to the significant market changes in the pharmaceutical industry.

The combination of those complementary businesses would create a broader portfolio of integrated business solutions and supported by the
- Richest global database of health professionals: Onekey
- Best in class CRM SaaS technologies: Mobile Intelligence

This is the recognition of the value of the Cegedim’s technology and strategic data service offerings

This transaction, if accepted, will provide flexibility to a strategic refocusing on attractive market such as software and databases for healthcare professionals, insurance companies, HR services and e-business activities
Expected Next Steps

1. Reception of the offer
2. Works Councils
3. Board of Directors
4. Regulatory Review
5. Group Reorganization
6. Transaction Closing

Information
Consultation
Reorganization
Transaction
Cegedim will remain a public company listed on NYSE Euronext Paris

1. CRM & STRATEGIC DATA
   - CRM
   - COMPLIANCE
   - ONEKEY
   - MARKET RESEARCH

For Healthcare Professionals
   - CHS
   - MEDEXACT
   - CEGELEASE
   - RNP
   - GERS
   - PHARMASTOCK

For Healthcare Insurance
   - CEGEDIM ASSURANCES

For Multi-Industry
   - CEGEDIM E BUSINESS
   - CEGEDIM SRH
   - KADRIGE

Revenue: €478m  EBITDA: €92m
Cegedim Will Remain on Attractive Markets

**Cegedim SRH**
- Vertical and complete offer
- Time management
- Sustained Growth

**e-business**
- Complete offer from dematerialization to Payment
- Steady Increase in Volume

**CHS**
- Connecting Patient to Doctor and Pharmacist
- Pay for Performance
- Integration of Connected Devices
- Cloud-based Solution

**RNP**
- Digital Offer

**Cegedim Insurance**
- Generalization of the third-party payment to doctors
- Unique vertical offer
- Strong demand for outsourcing

**Kadrige**
- Collaborative Technology

Attractive Market
Expected Transaction Impact Overview

If the offer is accepted:

- Revenue: €902.3m > €477.8m
- Revenue Growth: % 2.1 > +1.8%
- EBITDA: €155.7m > €92.2m
- EBITDA Margin: % 17.3 > 19.3%
- Net Debt: €462.0m > €77.0m
- Leverage: 3.0x > 0.8x
- Shareholders Equity: €345.8m > €8,000
- Employees: > 3,500

The transaction would lead to a significant improvement on Margin and Leverage ratio.

The major part of the proceeds would be used to repay the debt.

Significant impairment of goodwill expected. The figure is under review.

For illustrative purposes, this is based on 2013 figures excluding inter-Group transactions. These figures are unaudited.
2014 Target: Margin Improvement

- Debt reduction
- Improve operating leverage

Expect at least a stable
- Revenue level
- Margin level

Medium Term Target

These projections are publicly disclosed on June 25th, 2014. The fact that Cegedim includes these projections in this presentation should not be taken to mean that these projections continue to be our projections as of any subsequent date.
Key Take Aways

**THE PROPOSED TRANSACTION**

- **Offer from IMS Health to buy the major part of the CRM & Strategic Data division**
- **An attractive price of €385m**
- **Offer valid until November 30, 2014**
- **If accepted closing in early 2015**

**IMPACTS if accepted**

- **A decrease** in leverage from 3.0x to around 1.0x (1)
- **An increase** in EBITDA margin by 200bps
- **Strategic refocusing** on attractiv market
- **Significant increase** in Group financial flexibility
- **Significant impairment of goodwill expected** (2)
- **Cegedim will remain** listed on NYSE Euronext Paris

(1) Based on 2013 proforma figures. Only for illustrative purpose
(2) The figure is under review

Recognition of the value of our technology and strategic data service offerings.
Our IR App is now available

The Cegedim IR app for Android, iPhone and iPad allows you to follow Cegedim financial news, to find all the relevant information for investors and journalists and to receive customizable push notifications. Agenda, stock data, quarterly and annual reports, financial press releases, financial presentations, fact sheet, video, possibility to add events to your calendar, contacts details…

More features, especially for bond investors, are planned for the near future. We would appreciate your feedback on how to improve this app:
investor.relations@cegedim.com

This app is updated on the same time as our website.

iPhone is the exclusive property of Apple Inc., registered in the U.S. and other countries.
Samsung Nexus Tablet is a trademark of Samsung Electronics Co., Ltd. Android is a trademark of Google Inc.
July 29th
Q2-2014 Revenue

Available

This Document includes the Q1-2014 Financial Statements and Management Report
2014 Financial Agenda

- January 28, 2014: 2013 Revenue
- March 10, 2014: 2013 Results
- March 11, 2014: Analysts Meeting
- April 29, 2014: Q1 2014 Revenue
- May 27, 2014: Q1 2014 Results
- July 29, 2014: Q2 2014 Revenue
- September 18, 2014: Q2 2014 Results
- October 28, 2014: Q3 2014 Revenue
- November 27, 2014: Q3 2014 Results
We welcome your questions and comments

Jan Eryk UMIASTOWSKI
Chief Investment Officer
Head of Investor Relations

Janeryk.umiastawski@cegedim.com
www.cegedim.com/finance

TEL: +33 (0) 1 49 09 33 36